Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease

Combination therapy and comorbidity relevant to cardiac QT prolongation are common in patients with Parkinson's disease. Strategies to reduce the proportion of patients at risk from iatrogenic adverse cardiac events are warranted.